Browse studies

Find your next paid study

179 recruiting studies matching your filters

A Phase 1a/1b Study of NRM-823 as Monotherapy and in Combination With Immune Checkpoint Inhibition in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

This study is being done to find out of NRM-823 is safe and can treat participants with locally advanced or metastatic solid tumors.

HNSCCESCCEsophageal Adenocarcinoma+7 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Normunity AccelCo, Inc.NCT07182149

Phase 4

The Conventional Pipelle vs the Curved Aspirator Device: a Randomized Controlled Trial

The primary aim of this study is to rigorously compare the efficacy of two commonly used endometrial sampling devices, the Pipelle and the Miltex, these device…

Endometrial Biopsy

Estimated

~$25 – $1,500

Actual pay is set by the research site.

Jefferson DrapkinNCT07513493

Phase 1

A Phase 1 First-in-Human Study of PTK7-Directed Antibody Drug Conjugate HWK-007 in Participants With Advanced Solid Tumors

HWK-007-101 is a multicenter, open-label, first-in-human (FIH) Phase 1 study evaluating HWK-007, a protein tyrosine kinase 7 (PTK7)-targeted antibody drug conj…

Endometrial CancerOvarian CancerOvarian Cancer Metastatic+4 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Whitehawk Therapeutics, Inc.NCT07444814

Phase 2

An Open-label, Global, Multi-Arm Study to Evaluate the Efficacy and Safety of Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers (BELLA)

This is a Phase 2, open-label, global, multi-arm study to evaluate efficacy and safety of relacorilant in combination with other treatments in patients with gy…

Ovarian CancerFallopian Tube CancerPeritoneal Neoplasms+1 more

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Corcept TherapeuticsNCT06906341

Phase 3

A Phase 3, Multicenter, Randomized, Open-label Trial of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy With or Without Radiotherapy as Adjuvant Treatment for HER2-Expressing (IHC 3+/2+) Endometrial Cancer (DESTINY-Endometrial02/ GOG-3122/ ENGOT-en30/GINECO)

This study is designed to assess efficacy and safety of T-DXd adjuvant therapy, with or without radiotherapy, post-surgery in anticancer treatment naïve (inclu…

Endometrial Cancer

Estimated

~$50 – $2,250

Actual pay is set by the research site.

Daiichi SankyoNCT07022483

Outcomes of Low-Risk Endometrial Cancer With Isolated Tumor Cells in the Sentinel Lymph Nodes: a Prospective Multicenter Single-Arm Observational Study

This study evaluates whether isolated tumor cells in the first lymph nodes near the tumor can tell researchers something important about the future of patients…

FIGO Grade 1 Endometrial Endometrioid AdenocarcinomaFIGO Grade 2 Endometrial Endometrioid AdenocarcinomaStage IA1 Endometrial Cancer FIGO 2023+1 more

Estimated

~$10 – $750

Actual pay is set by the research site.

Mayo ClinicNCT06689956

Phase 1

A Multicenter Phase 1/2 Study to Investigate Safety, Tolerability, Pharmacokinetics, and Efficacy of the NaPi2B Antibody-Drug Conjugate TUB-040 in Patients With Recurrent or Progressive Uterine Endometrial Cancer After Platinum-Based Chemotherapy and Immune Checkpoint Inhibitor Therapy

The goal of this clinical study is to learn more about the study drug TUB-040, safety, tolerability, pharmacokinetics (PK), and effectiveness in treating patie…

Uterine Endometrial Cancer

Estimated

~$150 – $4,500

Actual pay is set by the research site.

Gilead SciencesNCT07743541

Phase 1

Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer

To find the recommended dose of the combination of avutometinib, defactinib, and everolimus in patients with endometrial cancer that is recurrent and has abnor…

Phase IBAvutometinibRAS Pathway+1 more

Estimated

~$150 – $3,000

Actual pay is set by the research site.

M.D. Anderson Cancer CenterNCT07318324

Phase 1

A Phase 1/2, First-in-human, Multicenter Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

A Study of Emi-Le in Participants with Solid Tumors

Triple Negative Breast CancerBreast CancerEndometrial Cancer+4 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Day One Biopharmaceuticals, Inc.NCT05377996

SEntinel Lymph Node Endometrial Cancer Trial: A Prospective Multicenter International Single-Arm Observational Trial (SELECT)

This study is being done to find out how often endometrial cancer recurs after the standard treatment as well as how often the standard treatment results in a …

Endometrial CancerEndometrioid AdenocarcinomaEndometrial Cancer Stage I

Estimated

~$10 – $750

Actual pay is set by the research site.

Memorial Sloan Kettering Cancer CenterNCT04291612

Endometrial Cancer, Risk Factors and Prevention Strategies: Perspectives of Patients and At-Risk Women

To learn more about women's attitudes toward and knowledge about endometrial cancer and options that might decrease the risk of developing

Endometrial Cancer

Estimated

~$10 – $750

Actual pay is set by the research site.

M.D. Anderson Cancer CenterNCT06409052

Phase 2

A Randomized, Window of Opportunity Trial of Tirzepatide in Women With Obesity and a Diagnosis of Endometrial Intra-epithelial Neoplasia (EIN) or Grade 1 Endometrial Cancer

The goal of this study is to determine the anti-proliferative effect of tirzepatide on the endometrium of patients with endometrial intra-epithelial neoplasia …

Endometrial CancerEndometrial Intraepithelial NeoplasiaGrade 1 Endometrial Endometrioid Carcinoma

Estimated

~$75 – $2,000

Actual pay is set by the research site.

UNC Lineberger Comprehensive Cancer CenterNCT07078838